Palvella Therapeutics (NASDAQ:PVLA) Releases Earnings Results, Misses Expectations By $0.30 EPS

Key Points

• Palvella Therapeutics reported quarterly EPS of ($1.20), missing analysts’ expectations of ($0.90) by $0.30.
• The company said its Phase III SELVA trial for QTORIN rapamycin met its primary and key secondary endpoints, keeping the NDA submission on track for H2 2026 and a possible H1 2027 approval.
• Palvella strengthened its balance sheet with a $230 million financing and ended Q1 with $261.9 million in cash, which management says should fund the company into a potential commercial launch.

Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) announced its earnings results on Thursday. The company reported ($1.20) earnings per share for the quarter, missing analysts' consensus estimates of ($0.90) by ($0.30), FiscalAI reports.

Here are the key takeaways from Palvella Therapeutics' conference call:

• Phase III SELVA for QTORIN rapamycin met the primary and all key secondary endpoints with a tolerable safety profile, and Palvella says an NDA submission remains on track for H2 2026 with an in-person pre-NDA meeting this quarter toward a potential H1 2027 approval.
• The company completed an upsized $230 million financing and ended Q1 with $261.9 million in cash, which management says provides runway into a potential commercial launch and through cash-flow break-even under current assumptions.
• Palvella is scaling commercial readiness—hiring experienced rare-disease launch leaders, expanding MSL coverage, and targeting a 30–40 rep field force pre-PDUFA—while estimating peak U.S. MLM sales >$1 billion and potential orphan pricing of $100k–$200k per patient per year.
• Pipeline momentum extends beyond MLM: phase III planning for cutaneous venous malformations is on track for H2 2026, the phase II LOTU angiokeratoma study has dosed its first patients ahead of schedule, and a DSAP phase II is targeted for H2 2026 amid strong patient interest.
• Management highlights the QTORIN platform as a differentiator—demonstrating dermal delivery of high‑molecular‑weight rapamycin, supported by multiple issued patents and formulation/manufacturing know‑how aimed at creating durable exclusivity and barriers to competition.

Palvella Therapeutics Price Performance

Shares of PVLA stock traded up $8.03 during mid-day trading on Friday, hitting $121.29. The company had a trading volume of 231,535 shares, compared to its average volume of 212,329. Palvella Therapeutics has a 52-week low of $20.20 and a 52-week high of $151.18. The stock's 50 day moving average price is $126.26 and its 200-day moving average price is $102.43.

Analysts Set New Price Targets

Several research analysts have issued reports on PVLA shares. HC Wainwright lifted their target price on shares of Palvella Therapeutics from $255.00 to $270.00 and gave the stock a "buy" rating in a report on Tuesday, March 24th. Wall Street Zen cut shares of Palvella Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, April 11th. TD Cowen restated a "buy" rating on shares of Palvella Therapeutics in a research report on Monday, February 2nd. Stifel Nicolaus set a $250.00 target price on shares of Palvella Therapeutics in a research report on Tuesday, February 24th. Finally, Truist Financial set a $210.00 target price on shares of Palvella Therapeutics in a research report on Tuesday, February 24th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Palvella Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $198.07.

Insider Transactions at Palvella Therapeutics

In other news, COO Kathleen Goin sold 4,302 shares of the business's stock in a transaction on Wednesday, March 18th. The shares were sold at an average price of $117.99, for a total value of $507,592.98. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Elaine J. Heron purchased 2,400 shares of the firm's stock in a transaction that occurred on Friday, February 27th. The shares were acquired at an average cost of $125.00 per share, for a total transaction of $300,000.00. Following the purchase, the director owned 47,812 shares of the company's stock, valued at $5,976,500. This represents a 5.28% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders own 20.50% of the company's stock.

Institutional Investors Weigh In On Palvella Therapeutics

A number of hedge funds have recently bought and sold shares of PVLA. Vanguard Group Inc. raised its stake in Palvella Therapeutics by 202.0% during the third quarter. Vanguard Group Inc. now owns 494,656 shares of the company's stock valued at $31,010,000 after purchasing an additional 330,847 shares in the last quarter. State Street Corp raised its stake in Palvella Therapeutics by 206.3% during the fourth quarter. State Street Corp now owns 420,462 shares of the company's stock valued at $44,010,000 after purchasing an additional 283,211 shares in the last quarter. Millennium Management LLC purchased a new stake in shares of Palvella Therapeutics in the first quarter valued at $7,553,000. Artisan Partners Limited Partnership purchased a new stake in shares of Palvella Therapeutics in the fourth quarter valued at $22,143,000. Finally, First Light Asset Management LLC raised its stake in shares of Palvella Therapeutics by 30.9% in the fourth quarter. First Light Asset Management LLC now owns 709,141 shares of the company's stock valued at $74,226,000 after acquiring an additional 167,597 shares during the period. Hedge funds and other institutional investors own 40.11% of the company's stock.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc NASDAQ: PVLA is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella's pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.